GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Artiva Biotherapeutics Inc (NAS:ARTV) » Definitions » Debt-to-Asset

ARTV (Artiva Biotherapeutics) Debt-to-Asset : 0.07 (As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Artiva Biotherapeutics Debt-to-Asset?

Artiva Biotherapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $3.73 Mil. Artiva Biotherapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $11.24 Mil. Artiva Biotherapeutics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2024 was $225.60 Mil. Artiva Biotherapeutics's debt to asset for the quarter that ended in Sep. 2024 was 0.07.

Artiva Biotherapeutics Debt-to-Asset Historical Data

The historical data trend for Artiva Biotherapeutics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Artiva Biotherapeutics Debt-to-Asset Chart

Artiva Biotherapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Asset
1.62 0.07 0.01 0.15 0.16

Artiva Biotherapeutics Quarterly Data
Sep20 Dec20 Mar21 Sep21 Dec21 Mar22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.16 0.18 0.21 0.07

Competitive Comparison of Artiva Biotherapeutics's Debt-to-Asset

For the Biotechnology subindustry, Artiva Biotherapeutics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Artiva Biotherapeutics's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Artiva Biotherapeutics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Artiva Biotherapeutics's Debt-to-Asset falls into.


Artiva Biotherapeutics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Artiva Biotherapeutics's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(3.596 + 13.316) / 105.114
=0.16

Artiva Biotherapeutics's Debt-to-Asset for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(3.733 + 11.235) / 225.596
=0.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Artiva Biotherapeutics  (NAS:ARTV) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Artiva Biotherapeutics Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Artiva Biotherapeutics's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Artiva Biotherapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Artiva Biotherapeutics Inc (NAS:ARTV) » Definitions » Debt-to-Asset
Comparable Companies
XBIT HLVX ZURA SKYE AVTX MNOV JSPR DOMH GALT TNYA VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
5505 Morehouse Drive, Suite 100, San Diego, CA, USA, 92121
Website
https://www.artivabio.com
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials.